Valuation: BioRestorative Therapies, Inc.

Market Cap 3.25M 2.85M 2.69M 2.45M 4.59M 311M 4.63M 32.22M 12.48M 159M 12.2M 11.93M 511M P/E 2026 *
-0.26x
P/E 2027 * -0.31x
Enterprise Value 3.25M 2.85M 2.69M 2.45M 4.59M 311M 4.63M 32.22M 12.48M 159M 12.2M 11.93M 511M EV / Sales 2026 *
2.31x
EV / Sales 2027 * 1.4x
Free-Float
90.44%
Yield 2026 *
-
Yield 2027 * -
1 day+1.59%
1 week-5.20%
Current month-37.01%
1 month-42.70%
3 months-67.64%
6 months-58.87%
Current year-89.15%
1 week 2.44
Extreme 2.445
2.93
1 month 2.44
Extreme 2.445
4.5
Current year 2.44
Extreme 2.445
25.6
1 year 2.44
Extreme 2.445
34.6
3 years 2.44
Extreme 2.445
73.4
5 years 2.44
Extreme 2.445
480
10 years 2.44
Extreme 2.445
400,800
Manager TitleAgeSince
Chief Executive Officer 28 2026-08-26
Director of Finance/CFO 38 2026-08-26
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 28 2026-06-11
Director/Board Member 37 2026-06-11
Director/Board Member - 2026-07-12
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/25 Free

Chief Technology Officer

23,438 0.2938%
10/6/25 Free

Chief Executive Officer

27,344 0.3427%
2/14/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%-5.20%-91.21%-91.67% 3.2M
-3.30%+1.50%+51.24%+99.26% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
-3.06%-1.81%-13.10%+357.06% 26.54B
-0.75%+2.56%+0.45%-4.46% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-2.12%+146.86%+314.52% 15.03B
+0.36%-0.34%+50.32%+166.42% 14.36B
+0.21%+1.17%-8.07%+499.10% 14.2B
Average -0.29%-0.47%+23.20%+142.90% 27.41B
Weighted average by Cap. -0.78%-0.02%+36.12%+130.11%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.16M 1.06M 1.99M 135M 2M 13.93M 5.4M 68.8M 5.28M 5.16M 221M 2.31M 2.03M 1.92M 1.75M 3.27M 222M 3.29M 22.93M 8.88M 113M 8.68M 8.49M 364M
Net income -13.52M -11.87M -11.21M -10.21M -19.12M -1.3B -19.26M -134M -51.95M -662M -50.78M -49.68M -2.13B -15.56M -13.65M -12.89M -11.75M -22M -1.49B -22.15M -154M -59.76M -762M -58.42M -57.15M -2.45B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
26-09-25 US$2.550 +1.59% 28,872
26-09-24 US$2.510 -3.46% 24,715
26-09-23 US$2.600 +1.96% 85,219
26-09-22 US$2.550 -5.90% 67,181
26-09-21 US$2.710 +0.74% 26,905
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.550USD
Average target price
160.00USD
Spread / Average Target
+6,174.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock